Delivery Order SPE2DB22D3501-SPE2DB25FUE42

Award Date 1/16/25
Potential Completion Date 1/17/25
Potential Value $28K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $56,253.69 firm fixed-price delivery order contract has a completion date of February 25, 2025. This award is part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award is a delivery order from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for DUPIXENT 300 MG/2 ML PEN 2ML. The $36,279.84 firm fixed price contract has a completion date of February 27, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
This federal contract award is for the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML, awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $15,028.03 firm fixed-price delivery order has a completion date of November 19, 2024 and is not set aside for any specific business type. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a...
This federal contract award is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $31,917.67 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a completion date of November 8, 2024 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $29,849.92 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract has a completion date of November 27, 2024 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products to the Defense Logistics Agency (DLA). The $12,633.87 fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on August 5, 2024 with a completion date of August 6, 2024. The contract is not designated with any set-aside requirements. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order with a firm fixed price of $79,621.50 and a completion date of June 4, 2024. The award is for the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This contract is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML. The contract has a ceiling value of $5,138.82 and is a firm fixed price delivery order that runs through January 30, 2025. This award is not designated as a set-aside contract. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award is for the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML, which was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $10,256.76, is a Delivery Order contract with a Firm Fixed Price pricing type. The contracting agency is the Defense Logistics Agency (DLA), a defense agency responsible for providing logistics, acquisitions, and technical services to the U.S. Armed Forces. This...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,770.38 fixed-price delivery order is for DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of November 18, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FUE42
    Delivery Order

This federal contract award is for the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML, awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $27,568.98 firm fixed-price delivery order contract runs until January 17, 2025.

The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.

Generated 4/18/25, 3:57 AM